Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787605 · ClinicalTrials.gov registry record · Phase 4
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 860
- Enrollment target
NCT00787605 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 860 participants.
The verdict
NCT00787605, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 860 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting systolic blood pressure (msSBP) ≥ 160 mm Hg and \< 200 mm Hg).
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Hydrochlorothiazide (HCTZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787605
The ClinicalTrials.gov registry entry for NCT00787605 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Amlodipine is the first listed.
NCT00787605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787605 about?
NCT00787605 is a clinical study titled "Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus". The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting systolic blood pressure (msSBP) ≥ 160 mm Hg and \< 200 mm Hg).
What is the current status of trial NCT00787605?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 860 participants. The study started on 2008-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00787605?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (HCTZ) (DRUG).
Who is sponsoring clinical trial NCT00787605?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.